Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Rajesh Alajangi"'
Autor:
Macarena Oporto Espuelas, Saskia Burridge, Amy A. Kirkwood, Denise Bonney, Kelly Watts, Geoff Shenton, Katarzyna A. Jalowiec, Maeve A. O’Reilly, Claire Roddie, Anna Castleton, Katherine Clesham, Emma Nicholson, Rajesh Alajangi, Shilpa Prabhu, Lindsay George, Ben Uttenthal, Maria Gabelli, Lorna Neill, Caroline Besley, Sridhar Chaganti, Robert F. Wynn, Jack Bartram, Robert Chiesa, Giovanna Lucchini, Vesna Pavasovic, Anupama Rao, Kanchan Rao, Juliana Silva, Sujith Samarasinghe, Ajay Vora, Peter Clark, Michelle Cummins, David I. Marks, Persis Amrolia, Rachael Hough, Sara Ghorashian
Publikováno v:
Blood Cancer Journal, Vol 14, Iss 1, Pp 1-10 (2024)
Abstract CAR T-cell therapy has transformed relapsed/refractory (r/r) B-cell precursor acute lymphoblastic leukaemia (B-ALL) management and outcomes, but following CAR T infusion, interventions are often needed. In a UK multicentre study, we retrospe
Externí odkaz:
https://doaj.org/article/1e1c7d0bb80d4261a46effd3f77c1a63
Autor:
Maeve A. O'Reilly, William Wilson, David Burns, Andrea Kuhnl, Frances Seymour, Ben Uttenthal, Caroline Besley, Rajesh Alajangi, Thomas Creasey, Shankara Paneesha, Johnathon Elliot, Carlos Gonzalez Arias, Sunil Iyengar, Matthew R. Wilson, Alison Delaney, Lourdes Rubio, Jonathan Lambert, Khalil Begg, Stephen Boyle, Kathleen P. L. Cheok, Graham P. Collins, Claire Roddie, Rod Johnson, Robin Sanderson
Publikováno v:
HemaSphere, Vol 8, Iss 6, Pp n/a-n/a (2024)
Abstract Brexucabtagene autoleucel (brexu‐cel) is an autologous CD19 CAR T‐cell product, approved for relapsed/refractory (r/r) mantle cell lymphoma (MCL). In ZUMA‐2, brexu‐cel demonstrated impressive responses in patients failing ≥2 lines,
Externí odkaz:
https://doaj.org/article/2580c990e3d748ad908ab8da5f93b054
Publikováno v:
British journal of haematology. 192(2)